{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:48:30Z","timestamp":1760237310881,"version":"build-2065373602"},"reference-count":22,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:00:00Z","timestamp":1585267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Cisplatin is a chemotherapeutic agent widely used for multiple indications. Unfortunately, in a substantial set of patients treated with cisplatin, dose-limiting acute kidney injury (AKI) occurs. Here, we assessed the association of 3 catechol-O-methyltransferase (COMT) single nucleotide polymorphisms (SNPs) with increased cisplatin-induced nephrotoxicity. In total, 551 patients were genotyped for the 1947 G&gt;A (Val158Met, rs4680), c.615 + 310 C&gt;T (rs4646316), and c.616\u2013367 C&gt;T (rs9332377) polymorphisms. Associations between these variants and AKI grade \u22653 were studied. The presence of a homozygous variant of c.616-367C&gt;T was associated with a decreased occurrence of AKI grade 3 toxicity (p = 0.014, odds ratio (OR) 0.201, 95% confidence interval (CI) (0.047\u20130.861)). However, we could not exclude the role of dehydration as a potential cause of AKI in 25 of the 27 patients with AKI grade 3, which potentially affected the results substantially. As a result of the low incidence of AKI grade 3 in this dataset, the lack of patients with a COMT variant, and the high number of patients with dehydration, the association between COMT variants and AKI does not seem clinically relevant.<\/jats:p>","DOI":"10.3390\/genes11040358","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T05:52:30Z","timestamp":1585720350000},"page":"358","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1825-2911","authenticated-orcid":false,"given":"Bram C.","family":"Agema","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"},{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stijn L.W.","family":"Koolen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"},{"name":"Department of Clinical Pharmacy, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9953-7945","authenticated-orcid":false,"given":"Mirjam","family":"de With","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"},{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"van Doorn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Heersche","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Oomen-de Hoop","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Visser","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"},{"name":"Department of Pulmonology, Amphia Hospital, 4818 CK Breda, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim G.J.V.","family":"Aerts","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"},{"name":"Department of Pulmonology, Amphia Hospital, 4818 CK Breda, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sander","family":"Bins","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron H.N.","family":"van Schaik","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,27]]},"reference":[{"key":"ref_1","unstructured":"Cisplatine, Informatorium Medicamentorum (2019). KNMP Kennisbank, KNMP."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of Cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins (Basel)"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1111\/bcp.13309","article-title":"Pharmacogenetic analysis of irreversible severe cisplatin-induced nephropathy: A case report of a 27-year-old woman","volume":"83","author":"Sanders","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.478","article-title":"Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy","volume":"41","author":"Ross","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/clpt.2013.121","article-title":"The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer","volume":"94","author":"Yang","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.arcmed.2008.10.006","article-title":"S-Adenosyl-L-methionine increases serum BUN and creatinine in cisplatin-treated mice","volume":"40","author":"Ochoa","year":"2009","journal-title":"Arch. Med. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6917","DOI":"10.1073\/pnas.111134598","article-title":"Effect of COMT Val108\/158 Met genotype on frontal lobe function and risk for schizophrenia","volume":"98","author":"Egan","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1503\/jpn.100059","article-title":"Pharmacogenetics of antidepressant response","volume":"36","author":"Porcelli","year":"2011","journal-title":"J. Psychiatry Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1086\/425589","article-title":"Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain","volume":"75","author":"Chen","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1373\/clinchem.2016.264986","article-title":"Analgesia and Opioids: A Pharmacogenetics Shortlist for Implementation in Clinical Practice","volume":"63","author":"Matic","year":"2017","journal-title":"Clin. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/srep00677","article-title":"COMT Val158Met polymorphism interacts with stressful life events and parental warmth to influence decision making","volume":"2","author":"He","year":"2012","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1800884","DOI":"10.1183\/13993003.00884-2018","article-title":"Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: A cohort study","volume":"52","author":"Visser","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_13","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) (2010). Edservices USdohah, National Institutes of Health."},{"key":"ref_14","unstructured":"KDIGO (2012). Clinical Practice Guideline for Acute Kidney Injury. Section 2: AKI defenition. Kidney Int. Suppl., 2, 1."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/FTD.0000000000000301","article-title":"Genetic Predisposition to Poor Opioid Response in Preterm Infants: Impact of KCNJ6 and COMT Polymorphisms on Pain Relief After Endotracheal Intubation","volume":"38","author":"Elens","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"eRW4007","DOI":"10.1590\/s1679-45082018rw4007","article-title":"Chemotherapy protocols and incidence of oral mucositis. An integrative review","volume":"16","author":"Curra","year":"2018","journal-title":"Einstein (Sao Paulo)"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncologist"},{"key":"ref_18","first-page":"72","article-title":"Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: Laboratory and clinical aspects","volume":"26","author":"Capizzi","year":"1999","journal-title":"Semin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.radonc.2003.10.005","article-title":"Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients","volume":"70","author":"Rades","year":"2004","journal-title":"Radiother. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/clpt.2009.139","article-title":"Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity","volume":"86","author":"Filipski","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/clpt.2013.145","article-title":"Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: Influence on antitumor efficacy and systemic clearance","volume":"94","author":"Sprowl","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1200\/JCO.2013.50.8184","article-title":"Can erlotinib ameliorate cisplatin-induced toxicities?","volume":"31","author":"Sprowl","year":"2013","journal-title":"J. Clin. Oncol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/11\/4\/358\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:12:17Z","timestamp":1760173937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/11\/4\/358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,27]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["genes11040358"],"URL":"https:\/\/doi.org\/10.3390\/genes11040358","relation":{},"ISSN":["2073-4425"],"issn-type":[{"type":"electronic","value":"2073-4425"}],"subject":[],"published":{"date-parts":[[2020,3,27]]}}}